RAPT Therapeutics/$RAPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About RAPT Therapeutics
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Ticker
$RAPT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
67
ISIN
US75382E1091
Website
RAPT Metrics
BasicAdvanced
$123M
-
-$1.37
-0.04
-
Price and volume
Market cap
$123M
Beta
-0.04
52-week high
$4.60
52-week low
$0.71
Average daily volume
1M
Financial strength
Current ratio
21.11
Quick ratio
20.659
Long term debt to equity
0.857
Total debt to equity
2.162
Management effectiveness
Return on assets (TTM)
-44.72%
Return on equity (TTM)
-75.60%
Valuation
Price to book
0.69
Price to tangible book (TTM)
0.69
Price to free cash flow (TTM)
-0.727
Growth
Earnings per share change (TTM)
-55.36%
3-year earnings per share growth (CAGR)
-18.79%
What the Analysts think about RAPT
Analyst ratings (Buy, Hold, Sell) for RAPT Therapeutics stock.
RAPT Financial Performance
Revenues and expenses
RAPT Earnings Performance
Company profitability
RAPT News
AllArticlesVideos
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
GlobeNewsWire·1 month ago
RAPT Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire·3 months ago
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for RAPT Therapeutics stock?
RAPT Therapeutics (RAPT) has a market cap of $123M as of May 30, 2025.
What is the P/E ratio for RAPT Therapeutics stock?
The price to earnings (P/E) ratio for RAPT Therapeutics (RAPT) stock is 0 as of May 30, 2025.
Does RAPT Therapeutics stock pay dividends?
No, RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next RAPT Therapeutics dividend payment date?
RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders.
What is the beta indicator for RAPT Therapeutics?
RAPT Therapeutics (RAPT) has a beta rating of -0.04. This means that it has an inverse relation to market volatility.